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A dwindling minority of countries now offer guaiac-based colorectal cancer (CRC) screening 
tests (including Croatia, Finland, Greece and Hungary) since, for over a decade, faecal 
immunochemical testing (FIT) has been shown to be more effective1.  FIT detects more 
positive results compared to guaiac-based tests with fewer false negatives and for 
participants is a more acceptable test. 
 
In Northern Ireland, three years on from when the UK National Screening Committee 
(UKNSC) recommended a move to FIT (in January 2016), no decision to support its 
implementation has been approved.  The inequity is unacceptable, as UKNSC published 
economic evidence showing FIT implementation would improve outcomes with cost 
savings2.   
 
Transition to FIT in England and Wales continues with additional plans to extend CRC 
screening to 50-74-year-olds announced (August 2018)3.  Scotland leads the way on this 
change.  Wisely, plans are being made to ensure sufficient investigative capacity.  Similarly, 
in the Republic of Ireland, the FIT-based screening programme (launched in 2012), received 
a commitment for full expansion to ensure coverage for 55-74-year-olds by 2021. 
 
Meanwhile, Northern Ireland approaches the second anniversary of collapsed devolved 
government and a longer period without a cancer strategy.  Elected officials vocalise the 
need to keep Northern Ireland in line with the rest of Great Britain (GB) and/or the Republic 
of Ireland (depending on their persuasion) in discussions of all things ‘Brexit’.  Sadly, in this 
case, they have been virtually silent when it comes to alignment issues pertaining to health 
and healthcare. 
 
The public health research community is increasingly frustrated by this reticence.  The 
Northern Ireland population is being left behind with an inferior screening test.  Moreover, 
since CRC screening is offered to 60-74-year-olds in Northern Ireland, those in their 50s will 
not have the option to undergo screening, unlike their GB counterparts, and this will widen 
regional health inequalities.  
 
When concerns were raised, the Permanent Secretary and HSC Chief Executive suggests 
that ‘extending the age range to 50 remains an option to be considered’.  Perhaps the 
evidence-based arguments endorsed in the rest of the UK have been diluted without a 
reasoned recourse to the high economic value of prevention.  This is worrying when the 
current trends suggest that CRC is increasing among younger people4.    
 
It is deeply concerning that a straightforward cost saving and evidenced-based policy 
change cannot be made in Northern Ireland to ensure the same access to FIT screening as 
other parts of the UK.  The potential impact on inequalities of changing to FIT should be 
welcomed since the evidence suggests that its uptake is improved in lower socioeconomic 
groups and its use improves participation rates5.     
 
Two decades on since the Good Friday agreement, political inaction (not bombs and bullets, 
thankfully) may be costing lives in Northern Ireland. It is time to safeguard public health and 
our health service.  “In any moment of decision, the best thing you can do is the right thing. 
The worst thing you can do is nothing.” ― Theodore Roosevelt  
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